Not recruiting
Chronic graft versus host disease in intestine+10
Not recruitingStudy on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies
Registered drugNo placebo
Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies
Registered drugNo placebo
- Substances:PanobinostatRuxolitinib+1
Countries:
Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Panobinostat



